Year 2023 / Volume 115 / Number 8
Original
Impact of proactive therapeutic drug monitoring of infliximab during the induction phase in IBD patients. A Bayesian approach

435-443

DOI: 10.17235/reed.2022.8781/2022

Lidia Serrano-Díaz, Carles Iniesta-Navalón, Rosa Gómez-Espín, Isabel Nicolás-de Prado, Enrique Bernal-Morell, Lorena Rentero-Redondo,

Abstract
Background and objectives: there is increasing evidence that proactive therapeutic drug monitoring in induction is useful to improve the control of inflammatory bowel disease (IBD), although it remains controversial. The primary objective of the study was to assess the short-term outcomes of proactive Bayesian therapeutic drug monitoring (TDM) during induction, to optimize infliximab (IFX) maintenance dose. Methods: retrospective observational cohort of IBD patients > 18 years. They were divided into two cohorts, standard therapy group (ST-group), with clinically based dose adjustment, and monitoring group (iTDM-group), with pharmacokinetic parameters calculated by Bayesian prediction at week 6 and individualized dosage regimens thereafter. In patients with an infliximab trough level (ITL) at week 6 below the optimal therapeutic range, the dose adjustment was performed at the first maintenance dose. Results: a total of 153 patients were included, 40 in the iTDM-group. Median ITL at week 6 during the induction period was 12.8 µg/ml (IRQ: 12.7) in this group. Only 16 patients (40.0 %) had ITL ≥ 15 µg/ml. Half of the patients (50.3 %) received intensified maintenance therapy during the study period (57.5 % iTDM vs 47.8 % ST, p = 0.291). The proportion of patients achieving primary response at week 14 was 51.8 %. When comparing the two groups, this proportion was higher in the iTDM group (74.3 % vs 44.2 %, p = 0.002). With regards to the variable “poor clinical outcomes” at week 26, this proportion was lower in the iTDM group (3.3 % iTDM vs 21.1 % ST, p = 0.024). Conclusions: proactive therapeutic drug monitoring using Bayesian approach is associated with higher primary response rates and fewer short-term complications.
Share Button
New comment
Comments
No comments for this article
References
1. Fernandes SR, Bernardo S, Simões C et al. Proactive Infliximab Drug Monitoring Is Superior to Conventional Management in Inflammatory Bowel Disease. Inflamm Bowel Dis 2020; 26:263-70.
2. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med 2005; 353:2462–76.
3. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease : the ACCENT I randomised trial. Lancet 2002; 359:1541–9.
4. Ford AC, Sandborn WJ, Khan KJ et al. Efficacy of Biological Therapies in Infl ammatory Bowel Disease : Systematic Review and Meta-Analysis. Am J Gastroenterol 2011; 106:644–59.
5. Papamichael K, Cheifetz AS, Melmed GY, et al. Appropriate Therapeutic Drug Monitoring of Biologic Agents. Clin Gastroenterol Hepatol 2019; 17:1655-68.
6. Zhang QW, Shen J, Zheng Q, et al. Loss of response to scheduled infliximab therapy for Crohn’s disease in adults: A systematic review and meta-analysis. J Dig Dis 2019; 20:65-72.
7. Beltrán B, Iborra M, Sáez-González E. Fecal Calprotectin Pretreatment and Induction Infliximab Levels for Prediction of Primary Nonresponse to Infliximab Therapy in Crohn’s Disease. Dig Dis 2019; 37:108–15.
8. Gisbert JP, Marín AC, McNicholl AG, et al. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. Aliment Pharmacol Ther 2015; 41:613-23.
9. Vande Casteele N, Ferrante M, Van Assche G, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology 2015; 148:1320-9.
10. DʼHaens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 2012; 18:2218–24
11. Syversen SW, Goll GL, Jorgensen KK, et al. Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases. A Randomized Clinical Trial. JAMA 2021;325:1744-54.
12. Cheifetz AS, Abreu MT, Afif W, et al. A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease. Am J Gastroenterol 2021;116:2014-25.
13. Papamichael K, Vajravelu RK, Byron P, et al. Proactive Infliximab Monitoring Following Reactive Testing is Associated With Better Clinical Outcomes Than Reactive Testing Alone in Patients With Inflammatory Bowel Disease. J Crohn´s Colitis 2018; 12:804-10.
14. Papamichael K, Casteele N Vande, Ferrante M, et al. Therapeutic Drug Monitoring during Induction of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: Defining a Therapeutic Drug Window. Inflamm. Bowel Dis 2017; 23:1510–5.
15. Shmais M, Hashash JG. Proactive versus Reactive Therapeutic Drug Monitoring: Why , When , and How ?. Inflamm Intest Dis 2022; 7:50-58.
16. Papamichael K, Stappen T Van, Casteele NV, et al. Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol 2016;14:543-9.
17. Papamichael K, Cheifetz AS. Infliximab concentrations during induction therapy — one size does not fit all. Aliment Pharmacol Ther 2018;47 1334-5.
18. Bar-Yoseph H, Levhar N, Selinger L, et al. Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapy. Aliment Pharmacol Ther 2018; 47:212–8.
19. Davidov Y, Ungar B, Bar-Yoseph H, et al. Association of Induction Infliximab Levels With Clinical Response in Perianal Crohn’s Disease. J Crohn´s Colitis 2017; 11:549–55.
20. Gil Candel M, Gascón Cánovas JJ, Urbieta Sanz E, et al. Usefulness of therapeutic drug monitoring of infliximab during the induction period in patients with inflammatory bowel disease. Rev Esp Enferm Dig 2020; 112:360-6.
21. Hoeve K van, Dreesen E, Hoffman I, et al. Adequate Infliximab Exposure During Induction Predicts. J Pediatr Gastroenterol Nutr 2019; 68:847–53.
22. Dreesen E, Faelens R, Van Assche G, et al. Optimising infliximab induction dosing for patients with ulcerative colitis. Br J Clin Pharmacol 2019;85:782-95.
23. Papamichael K, Vande Casteele N, Ferrante M, et al. Therapeutic Drug Monitoring During Induction of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: Defining a Therapeutic Drug Window. Inflamm Bowel Dis 2017; 23:1510-5.
24. Sparrow MP, Papamichael K, Ward MG, et al. Therapeutic Drug Monitoring of Biologics During Induction to Prevent Primary Non-Response. J Crohn’s Colitis 2020:543-56.
25. Martins CDA, Moss AC, Sobrado CW, et al. Practical Aspects of Proactive TDM for Anti-TNF Agents in IBD: Defining Time Points and Thresholds to Target. Crohn´s Colitis 360 2019;1:1-7.
26. Strik AS, Löwenberg M, Mould DR, et al. Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients ; a randomized controlled trial. Scand J Gastroenterol 2021;56:145-54.
27. Gil Candel M, Gascón Cánovas JJ, Gómez Espín R, et al. Usefulness of population pharmacokinetics to optimize the dosage regimen of infliximab in inflammatory bowel disease patients. Rev Esp Enferm Dig 2020;112: 590-7.
Related articles

Letter

Hepatosplenic T-cell lymphoma and inflammatory bowel disease

DOI: 10.17235/reed.2023.9472/2023

Review

Clinical settings with tofacitinib in ulcerative colitis

DOI: 10.17235/reed.2022.8660/2022

Letter

Anal neoplasia and perianal Crohn’s disease: myth or reality?

DOI: 10.17235/reed.2021.8317/2021

Letter

Apoptotic colopathy as a manifestation of Good’s syndrome

DOI: 10.17235/reed.2021.8297/2021

Original

Radon exposure and inflammatory bowel disease in a radon prone area

DOI: 10.17235/reed.2021.8239/2021

Review

Inflammatory bowel disease and solid organ transplantation

DOI: 10.17235/reed.2020.7361/2020

Editorial

Is celiac disease really associated with inflammatory bowel disease?

DOI: 10.17235/reed.2019.6779/2019

Original

Megacolon in inflammatory bowel disease: response to infliximab

DOI: 10.17235/reed.2020.6394/2019

Editorial

Diet in the etiology of inflammatory bowel disease

DOI: 10.17235/reed.2018.6119/2018

Case Report

Serrated Lesions in patients with Inflammatory Bowel Disease.

DOI: 10.17235/reed.2019.5910/2018

Editorial

Online social networks and inflammatory bowel disease

DOI: 10.17235/reed.2018.5496/2018

Letter to the Editor

Idiopathic portal hypertension with regard to thiopurine treatment

DOI: 10.17235/reed.2018.5256/2017

Editorial

Specialist care in the management of inflammatory bowel disease

DOI: 10.17235/reed.2016.4628/2016

Citation tools
Serrano-Díaz L, Iniesta-Navalón C, Gómez-Espín R, Nicolás-de Prado I, Bernal-Morell E, Rentero-Redondo L, et all. Impact of proactive therapeutic drug monitoring of infliximab during the induction phase in IBD patients. A Bayesian approach. 8781/2022


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 1268 visits.
This article has been downloaded 155 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 11/03/2022

Accepted: 01/12/2022

Online First: 23/12/2022

Published: 26/07/2023

Article revision time: 259 days

Article Online First time: 287 days

Article editing time: 502 days


Share
This article hasn't been rated yet.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2024 y Creative Commons. The Spanish Journal of Gastroenterology